TWA
PMCB icon

TCI Wealth Advisors’s PharmaCyte Biotech PMCB Stock Holding History

TCI Wealth Advisors’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3
Closed -$9 – 1679
2023
Q1 		$9 Hold
3
– – ﹤0.01% 2501
2022
Q4 		$9 Hold
3
– – ﹤0.01% 2476
2022
Q3 		$0 Hold
3
– – ﹤0.01% 2513
2022
Q2 		$0 Hold
3
– – ﹤0.01% 2463
2022
Q1 		$0 Hold
3
– – ﹤0.01% 2395
2021
Q4 		$0 Hold
3
– – ﹤0.01% 2464
2021
Q3 		$0 Buy
+3
New +$11 ﹤0.01% 2529

Other funds holding PMCB

AC
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TCI Wealth Advisors's PMCB Position: Q2 2023 in Review

TCI Wealth Advisors sold out of PharmaCyte Biotech (PMCB) in Q2 2023, closing a stake of 3 shares — an estimated $9 sold.

TCI Wealth Advisors first reported a position in PMCB in Q3 2021 and held it in 7 quarters. The position peaked at $9 in Q1 2023. 29 funds tracked by Wall St. Rank hold PMCB as of Q2 2023.

  • TCI Wealth Advisors reported no remaining PharmaCyte Biotech position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 3 PharmaCyte Biotech shares in Q2 2023, an estimated $9.
  • TCI Wealth Advisors first reported a position in PharmaCyte Biotech in Q3 2021 and held it in 7 quarters.
  • TCI Wealth Advisors's PharmaCyte Biotech position peaked at $9 in Q1 2023.
  • 29 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.